Among these gene-related disorders, familial platelet disorders with associated myeloid malignancy (FPD/AML), ankyrin repeat domain containing 26 related thrombocytopenia (ANKRD26-RT), and ETS variant transcription factor 6-related thrombocytopenia (ETV6-RT) require mutational screening of potential hematopoietic stem cell transplantation sibling donors, as patients with these gene variants have a high risk of developing hematological malignancies [8, 9]. This evidence concerns the gene ETV6 and cancer.